FREE Case Review (866) 588-0600

Onglyza Plaintiffs Want MDL for Heart Failure Lawsuits

A multidistrict litigation (MDL) has been proposed for all lawsuits involving allegations of heart failure from the type 2 diabetes medicine Onglyza.

A man who claims to have suffered heart failure from the types 2 diabetes medication Onglyza (generic: saxagliptin) has requested the centralization of all similar claims into a multidistrict litigation (MDL) for pretrial handling.

Free Confidential Lawsuit Evaluation: If you or a loved one has been injured by the side effects of Onglyza, you should contact our law firm immediately. You may be entitled to compensation by filing a suit and our lawyers can help.

What’s the Problem?

November 1, 2017 – Plaintiff in the Onglyza heart failure lawsuit claimed in a petition sent last month to the U.S. Judicial Panel on Multidistrict Litigation (JPML) that there are at least 40 other cases alleging similar injuries from Onglyza and Kombiglyze XR, another type 2 diabetes drug.

The man further claims that the cases are closely related – they share the same defendants, allegations, and damages – and that the resulting litigation will similarly include the same discovery, witnesses, and experts. Plaintiff says the litigation could eventually grow into the hundreds or even thousands, considering the large number of people prescribed the medicines.

Plaintiff suggested the Northern District of California as the venue for the proposed litigation, noting that several cases have already been filed there, and that at least one plaintiff is based in San Francisco.

He further notes in the petition that a judge in charge of a state-level Onglyza litigation in San Francisco has agreed to handle the MDL, if the motion is approved.

“The ability of the parties to conduct joint status conferences, a joint science day, and coordinate discovery between these two venues would be extremely beneficial for the parties, judges, and counsel,” Plaintiff claims.

Onglyza and Kombiglyze XR belong to the incretin mimetic class of diabetes drugs, which are designed to work by regulating levels of insulin the body produces after eating. Januvia (generic: sitagliptin), the first incretin mimetic sold in the U.S., is now listed on the U.S. Food & Drug Administration’s Do Not Use list. Galvus, another incretin mimetic, was rejected by the FDA over concerns about severe allergic reactions including Stevens-Johnson syndrome (SJS) and liver toxicity.

Do I Have an Onglyza Lawsuit?

The Pharmaceutical Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Onglyza lawsuits. We are handling individual litigation nationwide and currently accepting new injury and death cases in all 50 states.

Free Case Evaluation: Again, if you had side effects from a diabetes medication, you should contact our law firm immediately. You may be entitled to a settlement by filing a suit and we can help.

Free Confidential Case Evaluation

Verified 100% Secure SiteTo contact us for a free review of your potential case, please fill out the form below or call us toll free 24 hrs/day by dialing: (866) 588-0600.
Awards & recognition